FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
5 medicines are in FDA's class of hepatitis b virus nucleoside analog reverse transcriptase inhibitors: entecavir (Baraclude), lamivudine (Epivir), tenofovir disoproxil (Viread), adefovir dipivoxil and tenofovir alafenamide (Vemlidy); 17 combination products also contain one. 11 of the 22 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is entecavir 0.5 mg tablet at $0.219 per tablet (NADAC).
Which medicines are hepatitis b virus nucleoside analog reverse transcriptase inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Emtricitabine and tenofovir disoproxil | Truvada | 25 labelers | $0.529 per tablet 200-300 mg tablet | Yes | No current entry | 1 |
| Entecavir | Baraclude | 15 labelers | $0.219 per tablet 0.5 mg tablet | Yes | No current entry | 5 |
| Lamivudine | Epivir | 14 labelers | $0.489 per tablet 150 mg tablet | Yes | No current entry | 2 |
| Tenofovir disoproxil | Viread | 15 labelers | $0.294 per tablet 300 mg tablet | Yes | No current entry | 0 |
| Lamivudine and zidovudine | Combivir | 7 labelers | $0.771 per tablet Lamivudine-zidovudine tablet | Yes | No current entry | 1 |
| Efavirenz and emtricitabine and tenofovir disoproxil | none listed | 7 labelers | $1.12 per tablet 600-200-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and lamivudine | none listed | 6 labelers | $1.48 per unit 600-300 mg | Yes | No current entry | 0 |
| Bictegravir and emtricitabine and tenofovir alafenamide | Biktarvy | none listed | $136.73 per tablet 50-200-25 mg tablet | Yes | No current entry | 0 |
| Efavirenz and lamivudine and tenofovir disoproxil | Symfi | 1 labeler | n/a | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir disoproxil | Complera | 2 labelers | $114.50 per tablet 200-25-300 mg tablet | Yes | No current entry | 0 |
| Abacavir and dolutegravir and lamivudine | Triumeq | none listed | $130.01 per tablet 600-50-300 mg tablet | Yes | No current entry | 1 |
| Adefovir dipivoxil | none listed | 2 labelers | $21.73 per tablet 10 mg tablet | Yes | No current entry | 0 |
| Emtricitabine and tenofovir alafenamide | Descovy | none listed | $74.94 per tablet 200-25 mg tablet | Yes | No current entry | 0 |
| Abacavir and lamivudine and zidovudine | none listed | 1 labeler | n/a | Yes | No current entry | 0 |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Symtuza | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Genvoya | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil | Stribild | none listed | $150.14 per tablet Stribild tablet | Yes | No current entry | 0 |
| Dolutegravir and lamivudine | Dovato | none listed | $105.22 per tablet 50-300 mg tablet | Yes | No current entry | 0 |
| Doravirine and lamivudine and tenofovir disoproxil | Delstrigo | none listed | $93.06 per tablet 100-300-300 mg tablet | Yes | No current entry | 0 |
| Emtricitabine and rilpivirine and tenofovir alafenamide | Odefsey | none listed | $130.49 per tablet Odefsey tablet | Yes | No current entry | 0 |
| Lamivudine and tenofovir disoproxil | Cimduo | none listed | n/a | Yes | No current entry | 0 |
| Tenofovir alafenamide | Vemlidy | none listed | $51.98 per tablet 25 mg tablet | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price